Verastem Inc 's Revenue in the fiscal year 2025 $ 30.91 millions
Verastem Inc 's Revenue in the fiscal year 2024 $ 10.00 millions
Verastem Inc 's Revenue in the fiscal year 2023 $ 0.00 millions
Verastem Inc 's Revenue in the fiscal year 2022 $ 2.60 millions
Verastem Inc 's Revenue in the fiscal year 2021 $ 2.05 millions
VSTM Revenue third quarter 2026 Y/Y Growth Comment
Verastem Inc reported Revenue surge of 113.63% year on year in the third quarter 2026, to $ 24.01 millions, this is lower than Verastem Inc 's recent average Revenue surge of 122.63%.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 7 other companies have achieved higher Revenue growth. While Verastem Inc ' s Revenue doubling of 113.63% ranks overall at the positon no. 36 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Verastem Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
27150 %
1416.51 %
-100 %
(Dec 31 2021)
VSTM's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Verastem Inc disclosed fall in Revenue from the second quarter by -40.09% to $ 24.01 millions, from $ 40.08 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.
Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Verastem Inc 's Revenue growth quarter on quarter, overall rank is 123.
In the III. Quarter 2026 Verastem Inc disclosed fall in Revenue from the second quarter by -40.09% to $ 24.01 millions, from $ 40.08 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.
Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Verastem Inc 's Revenue growth quarter on quarter, overall rank is 123.
Verastem Inc 's 12 Months Revenue Growth Year on Year
Verastem Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 113.63% year on year, to $ 100 millions if the fiscal year would have ended in Sep 30 2026. Verastem Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2026. And, Verastem Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Jun 30 2026 rise was beneth at 14.59 % from $87.53 millions achieved in the period from Jun 30 2026 to Sep 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at130.24%.
Verastem Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
Verastem Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 113.63% year on year, to $ 100 millions if the fiscal year would have ended in Sep 30 2026. Verastem Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2026. And, Verastem Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Jun 30 2026 rise was beneth at 14.59 % from $87.53 millions achieved in the period from Jun 30 2026 to Sep 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at130.24%. The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 14.59 % increase from $87.53 millions in the period from Jun 30 2026 to Sep 30 2025.
Verastem Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
About Verastem Inc Revenue Growth Rates (VSTM), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
192.60%